These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Long-acting phenothiazines for treatment of schizophrenia. Med Lett Drugs Ther; 1976 Jan; 18(2):6-7. PubMed ID: 1107791 [No Abstract] [Full Text] [Related]
45. Weight changes with depot neuroleptic maintenance therapy. Johnson DA; Breen M Acta Psychiatr Scand; 1979 May; 59(5):525-8. PubMed ID: 463589 [TBL] [Abstract][Full Text] [Related]
46. [Characteristics of the psychotropic activity of long-acting drugs (experience in the use of Moditen-depot)]. Smulevich AB; Minsker EI; Mazaeva NA; Volkova RP; Lukanina SK Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(6):912-20. PubMed ID: 5050051 [No Abstract] [Full Text] [Related]
48. Dosage and side effect comparisons betweel oral and depot fluphenazine. Schooler NR; Levine J Psychopharmacol Bull; 1977 Jul; 13(3):29-31. PubMed ID: 329328 [No Abstract] [Full Text] [Related]
49. A comparative trial of the decanoates of flupenthixol and fluphenazine. Hamilton M; Card IR; Wallis GG; Mahmoud MR Psychopharmacology (Berl); 1979 Aug; 64(2):225-9. PubMed ID: 115046 [TBL] [Abstract][Full Text] [Related]
50. [Studies on the long acting neuroleptic agent flupenthixol decanoate--a review (author's transl)]. Sieberns S Pharmakopsychiatr Neuropsychopharmakol; 1978 Jul; 11(4):186-98. PubMed ID: 674354 [TBL] [Abstract][Full Text] [Related]
51. [Experiences with the depot-neuroleptic agent Dapotum D]. Teutsch H; Boissi KW Med Welt; 1974 Nov; 25(48):2027-32. PubMed ID: 4459664 [No Abstract] [Full Text] [Related]
52. A report on the use of flupenthixol in the maintenance treatment of psychotic patients at Ibadan, Nigeria. Jegede RO; Ibazebo H Afr J Psychiatry; 1981; 7(1-2):21-4. PubMed ID: 6122369 [No Abstract] [Full Text] [Related]
53. Depot neuroleptics in a community mental health service. Blake B Br Med J; 1979 Jul; 2(6181):48-9. PubMed ID: 466266 [No Abstract] [Full Text] [Related]
54. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia]. Tsutsul'kovskaia MIa; Minsker EI; Panteleeva GP; Mazurskii MB; Pekunova LG Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(5):753-8. PubMed ID: 4718619 [No Abstract] [Full Text] [Related]
55. [Clinical significance of depot fluphenazine decanoate in therapy of acute psychotic disorders]. Ngui PW Seishin Shinkeigaku Zasshi; 1983; 85(9):635-9. PubMed ID: 6676769 [No Abstract] [Full Text] [Related]
57. [Clinical observation on the effect of domestic fluphenazine decanoate in the treatment of schizophrenia---report of 431 cases (author's transl)]. Zhang YF Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1981 Aug; 14(3):182-5. PubMed ID: 7333179 [No Abstract] [Full Text] [Related]
59. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine. Schooler NR; Levine J Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413 [TBL] [Abstract][Full Text] [Related]